Hong Kong Mortgage Finance Stock News

China Resources Medical Holdings Company Limited ( HKG:1515 ) stock is about to trade ex-dividend in 3 days. The...

Readers hoping to buy China Reinsurance (Group) Corporation ( HKG:1508 ) for its dividend will need to make their move...

Oil prices have slipped back to pre conflict levels as tanker traffic resumes through the Strait of Hormuz, easing one of the biggest input costs for airlines and transportation stocks. At the same time, the situation still carries geopolitical risk, which can quickly feed back into fuel markets and sentiment. For investors, this mix of relief on costs and lingering tension can create both opportunities and reasons for caution. This article looks at 3 stocks from our Airlines and...

As Asian markets navigate a complex economic landscape marked by resilient industrial activity in China and monetary policy shifts in Japan, small-cap stocks are drawing attention for their potential value. In this environment, identifying promising small-cap opportunities often involves looking at companies with strong fundamentals and strategic insider actions that align with broader market trends.

Karrie International Holdings (SEHK:1050) has just reported its FY 2026 first half results, with revenue of HK$1,608.7 million, basic EPS of HK$0.050, and trailing 12 month net income of HK$270.9 million and EPS of HK$0.133 framing the latest read on profitability. The company has seen revenue move from HK$1,526.7 million in 1H FY 2025 to HK$1,704.7 million in 2H FY 2025 and then HK$1,608.7 million in 1H FY 2026. Over the same periods, basic EPS has tracked in a tight range around HK$0.050,...

ASMPT (SEHK:522) drew investor attention after securing a repeat order for eight Firebird Thermo Compression Bonding tools from a leading integrated device manufacturer. This highlighted the continued use of its equipment in high volume chip production. See our latest analysis for ASMPT. Beyond this repeat order, ASMPT’s recent share price performance has been strong, with a 30 day share price return of 8.78%, a 90 day share price return of 87.31%, and a 1 year total shareholder return of...

BYD stock performance sets the stage for valuation questions BYD (SEHK:1211) has come under pressure recently, with the stock down about 17% over the past month and about 26% over the past 3 months, prompting fresh scrutiny of its current valuation. Those moves sit against a longer track record that includes a year to date decline of about 23% and a total return decline of about 41% over the past year, even as the company reports sizeable revenue and net income. See our latest analysis for...

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Hilong Holding Limited ( HKG:1623 ) insiders who purchased shares in the last 12 months were richly rewarded last week...

Knowledge Atlas Technology (SEHK:2513) drew fresh attention after Elon Musk publicly discussed China’s AI capabilities, linking them to the company’s progress, with Zhipu AI’s CEO responding that reaching leading global model quality “won't take that long.” See our latest analysis for Knowledge Atlas Technology. Beyond the high profile comments on China’s AI capabilities, Knowledge Atlas Technology’s recent AGM brought a new independent non executive director, a rebrand to Z.AI Co., Ltd., and...

Lenovo Group (SEHK:992) recently expanded its Hybrid AI Advantage portfolio, introducing new AI inferencing and agentic AI tools aimed at helping enterprises deploy AI agents more efficiently and at lower operating cost across devices and data centers. See our latest analysis for Lenovo Group. The recent Hybrid AI announcements, new tablet launch and a completed US$2b zero coupon convertible bond sit against a backdrop of strong momentum, with a 30-day share price return of 45.52% and a...

Ascletis Pharma (SEHK:1672) has attracted investor attention after receiving U.S. FDA Investigational New Drug clearance for ASC35, a once-monthly dual GLP-1/GIP agonist that is being advanced into a Phase I obesity trial. See our latest analysis for Ascletis Pharma. The FDA IND clearance arrives after a volatile year for Ascletis Pharma, with the share price down 35.2% over the past month and 37.9% over three months, while still delivering a 3-year total shareholder return of 418.5% and a...

Global markets have been influenced by key developments, such as the Federal Reserve's decision to hold interest rates steady and the Bank of Japan's rate hike to a 31-year high. Against this backdrop, penny stocks—often representing smaller or newer companies—continue to offer intriguing opportunities for investors seeking growth potential at lower price points. While the term "penny stocks" may seem outdated, these investments can still present valuable prospects when they exhibit strong...

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Recent Performance Snapshot for Tencent Holdings stock Tencent Holdings (SEHK:700) has drawn investor attention after a period where the stock declined 4.2% over the past day, 7.3% over the past week and about 6% over the past month. Over the past 3 months, Tencent Holdings is down about 17.9%, with the year to date return showing a decline of 33.4%. On a 1 year basis, the total return is down 17.6%, while the 3 year total return stands at 25.1% and the 5 year total return reflects a decline...

Market forces rained on the parade of China Tobacco International (HK) Company Limited ( HKG:6055 ) shareholders today...

Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Tristate...

Growth has become harder to find as major economies send mixed signals, from weak European PMIs and contracting UK services to patchy strength across Asia and Latin America. In this kind of stop start backdrop, many investors are looking for companies where management is clearly aligned with shareholders and analysts see room for further expansion. The Fast Growing Stocks With High Insider Ownership screener focuses on exactly that combination. It highlights businesses where insiders have...

JBM (Healthcare) (SEHK:2161) has posted its FY 2026 first half results with revenue of HK$429.6 million and basic EPS of HK$0.141, setting the stage for how investors assess the latest move in profitability. The company has reported revenue of HK$398.9 million in FY 2025 H1, HK$383.3 million in FY 2025 H2, and HK$429.6 million in FY 2026 H1, while basic EPS was HK$0.116 in FY 2025 H1, HK$0.108 in FY 2025 H2, and HK$0.141 in the latest half. These figures sit against a slightly softer net...

Why the SSE 180 Index Addition Matters for COSCO SHIPPING Energy Transportation COSCO SHIPPING Energy Transportation (SEHK:1138) was recently added to the SSE 180 Index, a move that can draw more attention from institutional investors and index-tracking funds. This index inclusion often leads to higher visibility in the domestic market, which can influence trading volumes and liquidity. For existing and potential shareholders, the change raises questions about how the stock’s fundamentals...

Amidst a backdrop of shifting monetary policies and mixed economic signals in Asia, investors are closely watching regional markets for opportunities. Penny stocks, often associated with smaller or emerging companies, continue to capture interest due to their potential for substantial growth when supported by strong financials. While the term "penny stock" may seem outdated, the investment potential remains significant as these companies can offer unique value propositions that larger firms...

As the Asian markets navigate a complex landscape marked by geopolitical developments and monetary policy shifts, investors are on the lookout for opportunities that align with current economic conditions. Penny stocks, though often seen as relics of speculative trading, still offer potential when backed by strong financials and growth prospects. This article explores three penny stocks in Asia that stand out for their robust fundamentals, offering a unique opportunity for investors seeking...

China Medical System Holdings announced that its New Drug Application for Silevimig Injection, a fully human bispecific antibody for passive immunization after rabies exposure, was approved by China’s National Medical Products Administration on 22 June 2026, and the company obtained the drug registration certificate. This approval introduces the world’s first dual-epitope rabies bispecific antibody, adding an eighth commercialized innovative drug to the group’s portfolio and enhancing its...

In June 2026, InnoCare Pharma reported that over 40 clinical studies of its BTK inhibitor orelabrutinib were presented at the European Hematology Association Congress, highlighting consistent efficacy and safety across multiple blood cancers and patient populations in the United States, Europe, and China. Beyond confirming strong responses in chronic lymphocytic leukemia and marginal zone lymphoma, the data suggested orelabrutinib may offer a differentiated safety profile and meaningful...